Clinical Treatment in Urothelial Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 1 July 2026
Special Issue Editors
Interests: urology
Interests: urothelial carcinoma; renal cancer; molecular cancer biology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Urothelial cancer (UC) is a frequent malignancy of the urinary tract and represents a major burden in urologic oncology. Although treatment options have expanded in recent years, optimal management remains complex and varies widely according to disease stage and patient characteristics. This Special Issue presents current clinical approaches to the treatment of urothelial cancer, covering surgical management, radiotherapy, and systemic treatments, including chemotherapy and immunotherapy. Contributions also examine the role of biomarkers and molecular features in guiding treatment decisions, with particular focus on multidisciplinary care and its impact on treatment selection in routine clinical practice. The aim of this Special Issue is to present clinically relevant data and perspectives that reflect current practice and ongoing developments in the field.
Prof. Dr. Muhammad Shamim Khan
Dr. Yasmin Abu-Ghanem
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- urothelial cancer
- surgery
- systemic anti cancer therapy
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
